Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

istance. Preliminary analyses have shown that low-average levels of serum clusterin were predictive of the survival benefit. Additionally, patients treated with second-line chemotherapy plus OGX-011 experienced a reduction in pain that was durable as well as a decline in Prostate Specific Antigen (PSA). More information, including the ASCO data press release, is available on the company website at http://www.oncogenex.ca.

About OncoGenex

OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX 427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmacology studies. More information is available at http://www.oncogenex.ca.

Safe Harbor

This press release contains forward-looking statements, including statements concerning clinical trial results, future partnering activities and the economic benefits from developing OGX-011. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements regarding the timing and anticipated results of clinical trials and development efforts, future partnering activities and e
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers.  B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... 17, 2012 The " Anesthesia Drugs ... analyzes and studies the U.S. market for intravenous anesthesia drugs with ... buyers, export & import system for controlled substances in U.S. and U.S. ... in-depth TOC of   " Anesthesia Drugs ...
... clinical trial, a paralyzed woman was able to reach for and ... time in nearly 15 years by using her thoughts to ... the National Institutes of Health, is evaluating the safety and feasibility ... This is a type of brain-computer interface (BCI) intended to put ...
... 2012  Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... the Company,s common share repurchase program authorization by an ... of 2008, the Company has returned $236 million to ... and preferred shares, representing approximately 27% of its shares ...
Cached Biology Technology:Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 2Paralyzed individuals use thought-controlled robotic arm to reach and grasp 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 4Paralyzed individuals use thought-controlled robotic arm to reach and grasp 5Questcor Pharmaceuticals Expands Repurchase Program 2Questcor Pharmaceuticals Expands Repurchase Program 3Questcor Pharmaceuticals Expands Repurchase Program 4Questcor Pharmaceuticals Expands Repurchase Program 5
(Date:4/24/2014)... puts out a welcome mat to bacteria seeking to invade, ... study published this week in the Proceedings of the ... battle between microbe and host that researchers can exploit to ... oft-studied plant Arabidopsis puts out a molecular signal ... a hostile army were unknowingly passing by a castle, and ...
(Date:4/23/2014)... chronic inflammatory disorders among people of lower socioeconomic status ... to the microbes that thrive in rural environments, according ... in the journal Clinical & Experimental Immunology , ... less access to green spaces may be more apt ... system dysfunction. , When our immune systems are working ...
(Date:4/23/2014)... new study from the Indiana University School of Public ... and heart disease by finding a strong association between ... coronary heart disease. , The study found that heme ... by 57 percent, while no association was found between ... sources, and coronary heart disease. , The study was ...
Breaking Biology News(10 mins):How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3Study: Iron consumption can increase risk for heart disease 2
... Researchers have identified genetic markers that may influence whether ... according to a national longitudinal study of thousands of young ... Developmental Psychology , a publication of the American Psychological Association. ... related in any way to academic achievement is a big ...
... laparoscopic surgery "minimally invasive" instruments enter the patient through ... work on different tasks, surgeons all see the same view. ... suited to the specific task? In a new paper, pediatric ... Brown University and Hasbro Children,s Hospital report that in a ...
... Cancer Center have uncovered a single molecule they say ... used to treat or prevent breast cancer in high-risk ... Cancer Research , the scientists say glucose-regulated protein 78 ... the agents tamoxifen and fulvestrant, turns off apoptosis, a ...
Cached Biology News:Genes may play role in educational achievement, study finds 2Individual perspectives improve laparoscopy 2Individual perspectives improve laparoscopy 3Single protein promotes resistance to widely used anti-estrogen drugs 2Single protein promotes resistance to widely used anti-estrogen drugs 3
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
E2F-5...
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
Biology Products: